Evidence map›Paper›PMID 20042083›Full record

ArticleMicrobial cell factories2009

Performance of the auxotrophic Saccharomyces cerevisiae BY4741 as host for the production of IL-1beta in aerated fed-batch reactor: role of ACA supplementation, strain viability, and maintenance energy.

Lucia Paciello, Elisabetta de Alteriis, Cristina Mazzoni, Vanessa Palermo, Jesus Zueco, Palma Parascandola

Open access · goldAbstract read
In one paragraph

Article in Microbial cell factories, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Comparison of microbial hosts and expression systems for mammalian CYP1A1 catalysis.Journal of industrial microbiology & biotechnology · 2012
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Lucia PacielloDip to Ingegneria Chimica e Alimentare, Università di Salerno, Via Ponte Don Melillo, 84084 Fisciano, Salerno, Italy. lpaciello@unisa.it
Elisabetta de Alteriis
Cristina Mazzoni
Vanessa Palermo
Jesus Zueco
Palma Parascandola
Sapienza University of Rome · ITUniversity of Salerno · ITUniversitat de València · ESUniversity of Naples Federico II · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSaccharomyces cerevisiae BY4741 is an auxotrophic commonly used strain. In this work it has been used as host for the expression and secretion of human interleukin-1beta (IL1beta), using the cell wall protein Pir4 as fusion partner. To achieve high cell density and, consequently, high product yield, BY4741 [PIR4-IL1beta] was cultured in an aerated fed-batch reactor, using a defined mineral medium supplemented with casamino acids as ACA (auxotrophy-complementing amino acid) source. Also the S. cerevisiae mutant BY4741 Deltayca1 [PIR4-IL1beta], carrying the deletion of the YCA1 gene coding for a caspase-like protein involved in the apoptotic response, was cultured in aerated fed-batch reactor and compared to the parental strain, to test the effect of this mutation on strain robustness. Viability of the producer strains was examined during the runs and a mathematical model, which took into consideration the viable biomass present in the reactor and the glucose consumption for both growth and maintenance, was developed to describe and explain the time-course evolution of the process for both, the BY4741 parental and the BY4741 Deltayca1 mutant strain.

resultsOur results show that the concentrations of ACA in the feeding solution, corresponding to those routinely used in the literature, are limiting for the growth of S. cerevisiae BY4741 [PIR4-IL1beta] in fed-batch reactor. Even in the presence of a proper ACA supplementation, S. cerevisiae BY4741 [PIR4-IL1beta] did not achieve a high cell density. The Deltayca1 deletion did not have a beneficial effect on the overall performance of the strain, but it had a clear effect on its viability, which was not impaired during fed-batch operations, as shown by the kd value (0.0045 h-1), negligible if compared to that of the parental strain (0.028 h-1). However, independently of their robustness, both the parental and the Deltayca1 mutant ceased to grow early during fed-batch runs, both strains using most of the available carbon source for maintenance, rather than for further proliferation. The mathematical model used evidenced that the energy demand for maintenance was even higher in the case of the Deltayca1 mutant, accounting for the growth arrest observed despite the fact that cell viability remained comparatively high.

conclusionsThe paper points out the relevance of a proper ACA formulation for the outcome of a fed-batch reactor growth carried out with S. cerevisiae BY4741 [PIR4-IL1beta] strain and shows the sensitivity of this commonly used auxotrophic strain to aerated fed-batch operations. A Deltayca1 disruption was able to reduce the loss of viability, but not to improve the overall performance of the process. A mathematical model has been developed that is able to describe the behaviour of both the parental and mutant producer strain during fed-batch runs, and evidence the role played by the energy demand for maintenance in the outcome of the process.

Indexed as

Amino AcidsBiomassBioreactorsCaspasesFermentationGlucoseInterleukin-1betaRecombinant ProteinsSaccharomyces cerevisiaeSaccharomyces cerevisiae ProteinsAmino Acidscasamino acidsCaspasesGlucoseInterleukin-1betaMCA1 protein, S cerevisiaeRecombinant ProteinsSaccharomyces cerevisiae Proteins

Identifiers

PMID20042083
PMCPMC2806294
OpenAlexW2166850644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.